Renata PLC has completed shipment of its first consignment of Rosuvastatin–used for the prevention of cardiovascular disease—to the US market.

The listed local drugmaker exported the medication after manufacturing it at its Bangladesh factory approved by the US Food and Drug Administration, the company said in a statement.

Renata said the medicine offers American patients an alternative for cholesterol management, with identical quality and effectiveness to the original.

The product—better known by its brand name Rolip in the Bangladesh market—will be available in the US market as a bioequivalent and interchangeable formulation to the innovator product.

Rolip is available in dosage strengths of 5 mg, 10 mg, 20 mg, and 40 mg tablets.

This range ensures comprehensive treatment options for patients managing high cholesterol levels, according to the statement.

As a part of its launching campaign, Renata is supplying a total of 80 lakh units across various strengths with an aim to meet the growing demand for cholesterol management solutions.

This shipment marks yet another milestone for Renata in expanding its international presence and supporting the global fight against cardiovascular diseases, the company said.

Rolip joins Renata's mission of delivering an extensive portfolio of high-quality, bioequivalent generic medicines globally, in Bangladesh and beyond.